March 9 (Reuters) - Hims & Hers' shares were up over 40% on Monday, after Novo Nordisk agreed to sell its blockbuster Wegovy and Ozempic drugs through the telehealth firm's platform, signaling an end to the dispute between the two companies.

The crucial question is whether the terms of the partnership allow for profitable expansion or merely position HIMS as a low-margin distributor.

Two healthcare names are drawing fresh analyst attention this week as Wall Street recalibrates around a landmark GLP-1 truce and a fertility benefits company navigating a murky 2026 outlook. Barclays analyst Glen Santangelo raised his price target on Hims & Hers Health to $29 from $25,

Hims & Hers and Novo Nordisk have officially laid down their swords. | The agreement marks the end of a longstanding public feud and allows Hims & Hers to sell Novo's branded Ozempic and Wegovy on its telehealth platform.

HIMS stock soars on a settlement and partnership with Novo Nordisk. But Hims & Hers shares are unlikely to sustain these gains over time. The stock is still down some 38% versus its year-to-date high.

Yahoo Finance anchor Josh Lipton tracks Wednesday's top moving stocks and biggest market stories in this Market Minute. Hims & Hers Health (HIMS) stock is soaring after the company named Katherine Beir as its next chief communications officer,

Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two days after it announced the new drug

Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth.

Hims & Hers Health Inc. (NYSE:HIMS) is one of the 10 Stocks Making Huge Moves Today. Hims & Hers extended its winning streak to a third consecutive day on Wednesday, jumping 10.27 percent to close at $25.